Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The majority of small cell lung cancer(SCLC)(50-100%) express somatostatin receptors(type
1-5) with some small cell lung cancer express more than one subtypes. Stimulation of these
SSTR's lead to inhibition of angiogenesis and cell growth. SOM230 also lower levels of IGF
which is known to contribute to SCLC proliferation. Topotecan is approved for second line
therapy in relapsed small cell lung cancer. We hypothesized that combination of both agents
should yield greater antitumor activity.
Phase:
Phase 2
Details
Lead Sponsor:
South Florida Veterans Affairs Foundation for Research and Education